Lipella Pharmaceuticals
PITTSBURGH, PA · Biopharma, Biotechnology, Healthcare · 5 employees
Lipella is a biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis, also called radiation cystitis, when hemorrhagic cystitis occurs after pelvic radiation, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma. We are also applying our proprietary drug delivery to the oral mucosa for the treatmen
Funding history
- Series pre-seed — $9K — Apr 2025
- Series seed — $2.6M — Jan 2025
- Funding Round — $120K — Aug 2024
- Series seed — $3.1M — Nov 2023
- Series seed — $3.1M — May 2021
Recent signals
- Feb 03, 2026: SEC 8-K (5.02): On February 3, 2026, Lori A. Birder resigned from her position on the Board of Directors of Lipella Pharmaceuticals Inc., effective immediately. Her resignation was confirmed not to be related to any disagreements concerning the Company's operations, policies, or practices. This change may signal a shift in governance and could have implications for the strategic direction of the company. The timing of her departure immediately before the reporting date highlights the absence of any planned transition or succession announcement.
- Apr 01, 2025: Raised $9K in Series pre-seed
- Jan 07, 2025: Raised $2.6M in Series seed
- Aug 15, 2024: Raised $120K
- Aug 01, 2024: Lipella Pharmaceuticals Closes $1.28 Million Direct Offering of Common Stock Under Nasdaq Rules
- Nov 07, 2023: Raised $3.1M in Series seed
- May 17, 2021: Raised $3.1M in Series seed
- Apr 12, 2021: Raised $2.6M in Series seed
See plans & pricing → Track Lipella Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.